六年观察数据显示,德国因炎症性肠病而同时使用类固醇过量减少
Ann-Sophie Stratil1, Benjamin Friedrich1, Patrizia Brunner1
1Temedica GmbH, Munich, Germany.
Inflammatory bowel diseases
|May 13, 2025
概括
在炎症性肠病 (IBD) 中,口服皮质类固醇 (OCS) 的使用仍然很常见,特别是在克罗恩病患者中. 然而,OCS过度使用从2017年到2022年显著下降.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 口服皮质类固醇 (OCS) 维持疗法在炎症性肠病 (IBD) 中不建议,但经常使用.
- 本研究调查了2017年至2022年间德国IBD患者的OCS使用和过度使用模式.
研究的目的:
- 评估同时使用和过度使用口服皮质类固醇 (OCS) 的患有炎症性肠病 (IBD) 的患者的患病率和趋势.
- 确定与OCS使用和IBD过度使用相关的患者人口统计数据.
主要方法:
- 对2017-2022年德国索赔数据的回顾性分析.
- 包括接受IBD治疗的成年IBD患者 (克罗恩病[CD]和性结肠炎[UC]) 连续保险和两年内至少两次季度诊断,接受IBD治疗.
- 过度使用OCS的定义是,在一年内与其他IBD药物一起,OCS处方≥2次.
主要成果:
- 超过42%的克罗恩病 (CD) 和39%的性结肠炎 (UC) 患者同时使用OCS;31.3%的CD和29.4%的UC患者经历了OCS的过度使用.
- 同时使用OCS和过度使用在年轻IBD患者群体中更为普遍.
- 从2017年到2022年,OCS使用和过度使用的显著下降被观察到.
结论:
- 现实世界的数据显示,OCS在IBD管理中的依赖性持续,特别是在CD和年轻患者中.
- 尽管继续使用,但在研究期间观察到OCS过度使用的显著下降趋势.
- 研究结果强调需要优化IBD治疗策略,以尽量减少皮质类固醇暴露.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
87
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
87
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
105
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
105
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
Drugs for Treatment of Ulcerative Colitis in IBD
106
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
106
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
246
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
246
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
100
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
100


